#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Proton pump inhibitors – new molecules, new knowledge


Authors: J. Špičák;  K. Chmelová
Authors‘ workplace: Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha
Published in: Kardiol Rev Int Med 2016, 18(1): 67-75
Category: Cardiology Review

Overview

Proton pump inhibitors (PPI) are the primary medication in the treatment of acid-related diseases. All proton pump inhibitors are weak bases selectively metabolised in an acid environment which block the function of active proton pumps. Proton pump inhibitors provide efficient treatment for gastroesophageal reflux disease, Helicobacter pylori, functional dyspepsia and NSAID gastropathy. PPI may be helpful in patients with eosinophilic oesophagitis. PPI of the first generation comprise omeprazole, pantoprazole and lansoprazole, the second one is represented by esomeprazole and rabeprazole. Proton pump inhibitors differ in pharmacokinetic properties but these differences do not necessarily have clinically relevant consequences. Generally, second generation proton pump inhibitors provide a faster onset of effect, longer gastric secretion inhibition, and specifically the effect of rabeprazole is less dependent on the method of administration and has less influence on the function of cytochrome P450. The effect of proton pump inhibitors, particularly the first generation, is modified by the genetic variety of the CYP2C19 enzyme and is significantly lower in rapid metabolisers. Proton pump inhibitors are very safe and immediate complications are rare. They can cause progression of gastritis in Helicobacter infection. In spite of causing hypergastrinemia, they do not have malignant potential. Their long-term administration is associated with an increased risk of pelvis and hip fractures, community-acquired pneumonia, and clostridium infection. They decrease the effect of antiaggregant therapy with clopidogrel, and increase the risk of recurrent cardiovascular events. This effect is not proven in prasugrel. We cannot expect any potential progression in developing new molecules or PPI formulas. The instructions for patients are usually not clearly presented and often lack important information.

Keywords:
proton pump inhibitors – omeprazole – lansoprazole – pantoprazole – rabeprazole – esomeprazole – side effects – interactions


Sources

1. Huang JQ, Hunt RH. Pharmacological and pharmacodynamic es­sentials of H2-receptor antagonists and proton pump inhibitors for the practic­ing physicians. Best Practis Res Clin Gastroenterol 2001; 15: 355– 370.

2. Martínek J, Lukáš M. Inhibitory protonové pumpy –  up to date. Gastroent Hepatol 2011; 65: 231– 242.

3. Anders­son T, Weidolf L. Stereoselective disposition of proton pump inhibitors. Clin Drug Investig 2008; 28: 263– 279.

4. Morel­li G, Chen H, Ros­siter B et al. An open-label, paral­lel, multiple-dose study compar­ing the pharmacokinetics and gastrin acid suppres­sion of rabeprazole extended-realise with omeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment Pharmacol Ther 2011; 33: 845– 854. doi: 10.1111/ j.1365-2036.2011.04580.x.

5. Chiba N, De Gara CJ, Wilkinson JM et al. Speed of heal­ing and symp­tom relief in grade II to IV gastroesopohageal reflux disease: a metaanalysis. Gastroenterology 1997; 112: 1798– 1810.

6. Vakil N, Fen­nerty MB. Direct comparative trials of the ef­ficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 559– 568.

7. Maiti R, Jaida J, Israel J et al. Rabeprazole and esomeprazole in mild-to-moderate erosive gastroesophageal reflux disease: a comparative study of ef­ficacy and safety. J Pharmacol Pharmacother 2011; 2: 150– 157. doi: 10.4103/ 0976-500X.83278.

8. Maret-Ouda J, Brus­selaers N, Lagergren J. What is the most ef­fective treatment for severe gastro-oesophageal reflux disease? BMJ 2015; 350: 3169. doi: 10.1136/ bmj.h3169.

9. de Jonge PJ, Spaander MC, Bruna MJ et al. Acid suppres­sion and surgical therapy for Bar­rett's oesophagus. Best Pract Res Clin Gastroenterol 2015; 29: 139– 150. doi: 10.1016/ j.bpg.2014.11.005.

10. Jachimski P, Maqbool S, Bhat YM et al. Control of acid and duodenogastroesophageal reflux (DGER) in patients with Bar­rett's esofagus. Am J Gastroenterol 2015; 110: 1143– 1148. doi: 10.1038/ ajg.2015.161.

11. Sheikh I, Waghray A, Waghray N et al. Consumer use of over-the-counter proton pump inhibitors in patients with gastroesophageal reflux dis­ease. Am J Gastroenterol 2014; 109: 789– 794. doi: 10.1038/ ajg.2013.421.

12. Tang HL, Li Y, Hu YF et al. Ef­fects of CYP2C19 los­s--of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: A meta-anal­ysis of randomized clinical trials. PLoS One 2013; 8: e62162. doi: 10.1371/ journal.pone.0062162.

13. Tielemans MM, Eikendal T, Jansen JB et al. Identification of NSAID users at risk for gastrointestinal complications. Drug Saf 2010; 33: 443– 453. doi: 10.2165/ 11534590-000000000-00000

14. Iwamoto J, Saito Y, Honda A et al. Clinical features of gastroduodenal injury as­sociated with long-term low dose aspirin therapy. World J Gastroenterol 2013; 19: 1673– 1682. doi: 10.3748/ wjg.v19.i11.1673.

15. Lanza FI, Chan FK, Quigley EM et al. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728– 738. doi: 10.1038/ ajg.2009.

16. Washio E, Esaki M, Maehata Y et al. Proton pump inhibitors increase incidence od nonsteroidal anti--inflam­matory drug-induced small bowel injury: A randomized, placebo-control­led trial. Clin Gastroenterol Hepatol 2015; S1542-3565(15)01489-5. doi: 10.1016/ j.cgh.2015.10.022.

17. Liu B, Liu S, Yin A et al. Risks and benefits of stress ulcer prophylaxis in adult neurocritical care patients: a systematic review and metaanalysis of random­ized control­led trials. Critical Care 2015; 19: 409. doi: 10.1186/ s13054-015-1107-2.

18. Jian Z, Li H, Race NS et al. Is the Era of intravenous proton pump inhibitors com­ing to an end in patients with bleed­ing peptic ulcers? Meta-analysis of the published literature. Br J Clin Pharmacol 2015. [Ahead of print]. doi: 10.1111/ bcp.12866.

19. Fords A, Moayyedi P. Cur­rent guidelines for dyspepsia management. Dig Dis 2008; 26: 225– 230. doi: 10.1159/ 000121351.

20. Liacouras CA, Furuta GT, Hirano et al. Eosinophilic esophagitis: updated konsensus recom­mendations for children and adults. J Al­lergy Clin Im­munol 2011; 128: 3– 20. doi: 10.1016/ j.jaci.2011.02.040.

21. Vazquez-Elizondo G, Ngamruengphong S, Khrisna M et al. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther 2013; 38: 1312– 1319. doi: 10.1111/ apt.12513.

22. Lucendo AJ, Arias A, Molina-Infante J. Ef­ficacy of Proton pump inhibitor drugs for induc­ing clinical and histologic remis­sion in patients with symp­tomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 13– 22. doi: 10.1016/ j.cgh.2015.07.041.

23. Molina-Infante J, Rodriguez-Sanchez J, Martinek J et al. Long-term loss of response in proton pump inhibitor-responsive esophageal eosinophilia is uncom­mon and influenced by cyp2c19 genotype and rhinoconjunctivitis. Am J Gastroenterol 2015; 11: 1567– 1575. doi: 10.1038/ ajg.2015.314.

24. Lodato F, Azzyaroli F, Turco L et al. Adverse ef­fects of proton pump inhibitors. Best Pract Res Clin Gastroenterol 2010; 24: 193– 201. doi: 10.1016/ j.bpg.2009.11.004.

25. Fiocca R, Mastracci L, Attwood SE et al. Gastric exocrine and endocrine cell morfology under prolonged acid inhibition therapy: results of 5-year fol­low-up in the LOTUS trial. Aliment Pharmacol Ther 2012; 36: 959– 971. doi: 10.1111/ apt.12052.

26. Thomson AB, Sauve MD, Kas­sam N et al. Safety of long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16: 2323– 2330.

27. Yu EW, Bauer SR, Bain PA et al. Proton pump inhibitors and risk of fractures: a meta-analylsis of 11 internbational studies. Am J Med 2011; 124: 519– 526. doi: 10.1016/ j.amjmed.2011.01.007.

28. Zhou B, Huang Y, Li H et al. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int 2015. In press.

29. Yang SD, Chen Q, Wei HK et al. Bone fracture and the interaction between bisphosphonates and proton pump inhibitors: a meta-analysis. Int J Clin Exp Med 2015; 8: 4899– 4910.

30. Kieboom BC, Kiefte- de Jong JC, Eijgelsheim M et al. Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study. Am J Kidney Dis 2015; 66: 775– 782. doi: 10.1053/ j.ajkd.2015.05.012.

31. Sharara Al, Chalhoub JM, Ham­moud N et al. Low prevalence of hypomagnesemia in long-term recipients of proton pump inhibitors in a manage care cohort. Clin Gastroenterol Hepatol 2016; 14: 317– 321. doi: 10.1016/ j.cgh.2015.10.012.

32. Giuliano C, Wilhem SM, Kale-Pradhan PB. Are proton pump inhibitors as­sociated with the development of com­munity-acquired pneumonia? A meta-analysis. Expert Rev Clin Pharmacol 2012; 5: 337– 344. doi: 10.1586/ ecp.12.20.

33. Lambert AA, Lam JO, Paik JJ. Risk of com­munity--acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One 2015; 10: e0128004. doi: 10.1371/ journal.pone.0128004.

34. Freeman R, Dabrera G, Lane C et al. As­sociation between use of proton pump inhibitors and non-typhoidal salmonel­losis identified fol­low­ing investigation into an outbreak of Salmonel­la Mikawasima in the UK, 2013. Epidemiol Infect 2015; 1: 1– 8.

35. Deshpande A, Pant Ch, Pasupuleti V et al. As­sociation between proton pump inhibitor therapy and clostridium dif­ficile in a meta-analysis. Clin Gast-roenterol Hepatol 2012; 10: 225– 233. doi: 10.1016/ j.cgh.2011.09.030.

36. Ogawa R, Echizen H. Drug-drug interactions profiles of proton pump inhibitors. Clin Pharmacokinet 2010; 8: 509– 533. doi: 10.2165/ 11531320-000000000-00000.

37. Drepper MD, Spahr L, Fros­sard JL.Clopidogrel and proton pumpo inhibitors –  where do we stand in 2012? World J Gastroenterol 2012; 18: 2161– 2171. doi: 10.3748/ wjg.v18.i18.2161.

38. Roe MT, Armstrong PW, Fox KA et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med 2012; 367: 1297– 1309. doi: 10.1056/ NEJMoa1205512.

39. Hsieh CF, Huang WF, Chiang YT et al. Ef­fects of clopidogrel and proton pump inhibitors on cardiovascular events in patients with type 2 diabetes mel­litus after drug-elut­ing stent implantation: a nationwide cohort study. PLoS One 2015; 10: e0135915. doi: 10.1371/ journal.pone.0135915.

40. Col­let JP, Hulot JS, Abtan J et al. Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutraliz­ing ef­fect of P2Y12 inhibition: Results of the randomized DOSAPI study. Eur J Clin Pharmacol 2014; 70: 1049– 1057. doi: 10.1007/ s00228-014-1710-1.

41. Chen J, Yuan YC, Leontiadis GI et al. Recent safety concerns with proton pump inhibitors. J Clin Gastroenterol 2012; 46: 93– 114. doi: 10.1097/ MCG. 0b013e3182333820.

42. Cardoso RN, Benjo AM, DiNicolantonio JJ et al. Incidence of cardiovascular events and gastrointestinal bleed­ing in patients receiv­ing clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart 2015; 2: e000248. doi: 10.1136/ openhrt-2015-000248.

43. Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363: 1909– 1917. doi: 10.1056/ NEJMoa1007964.

44. Hulot JS, Col­let JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients accord­ing to cyto­chrome P450 2C19*2 los­s-of-function al­lele or proton pump inhibitor coadministration. J Am Coll Cardiol 2010; 56: 134– 143. doi: 10.1016/ j.jacc.2009.12.071.

45. Uotani T, Sugimoto M, Nishino M et al. Ability of rabeprazole to prevent gastrin mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19. Clin Gasteroenterol Hepatol 2012; 10: 879– 885. doi: 10.1016/ j.cgh.2012.04.016.

46. El-Halabi MM, Zgheuib N, Mansour NM et al. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no ef­fect on the anti-platelet action of clopidogrel. J Cardiovasc Pharmacol 2013; 62: 41– 49. doi: 10.1097/ FJC.0b013e31828ecf44.

47. Agewall S, Cattaneo M, Col­let JP et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013; 34: 1708– 1713. doi: 10.1093/ eurheartj/ eht042.

48. DeVault KR, Tal­ley NJ. Insights into the future of gastric acid suppres­sion. Nat Rev Gastroenterol Hepatol 2009; 6: 524– 532. doi: 10.1038/ nrgastro.2009.125.

49. Sachs G, Shin JM, Hunt R et al. Novel ap­proaches to inhibition of gastrin acid secretion. Curr Gastroenterol Rep 2010; 12: 437– 447. doi: 10.1007/ s11894-010-0149-5.

Labels
Paediatric cardiology Internal medicine Cardiac surgery Cardiology

Article was published in

Cardiology Review

Issue 1

2016 Issue 1

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#